SCHEMBL21654538

SCHEMBL21654538

Fc1ccc(/C=C/c2nnc(CCc3cccc(Br)c3)o2)c(Cl)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 3/20 0.35
GSK3B P49841 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TAAR1 Q96RJ0 3/20 0.33
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
KCNH2 Q12809 1/20 0.32
EGFR P00533 1/20 0.31
KDR P35968 1/20 0.31
METAP2 P50579 1/20 0.31
CNR1 P21554 2/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21654642 0.90 PTK2 (0.45) PTK2NPC1RAB9AL3MBTL1HTR2A
SCHEMBL21654805 0.82 NPC1 (0.36) PTK2NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL21654596 0.82 PTK2 (0.40) PTK2NPC1RAB9AL3MBTL1METAP2
SCHEMBL21654541 0.81 PTK2 (0.48) PTK2NPC1SMN1; SMN2HTR2AHTR2C
SCHEMBL21654822 0.81 NPC1 (0.37) PTK2NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL21654763 0.80 NPC1 (0.41) PTK2NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL21654528 0.80 EGFR (0.42) PTK2NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL21654539 0.79 PTK2 (0.47) PTK2NPC1RAB9ACYP1A2CYP2D6
SCHEMBL21654795 0.79 PTK2 (0.47) PTK2NPC1RAB9ACYP1A2CYP2D6
SCHEMBL21654797 0.79 PTK2 (0.44) PTK2NPC1RAB9ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11149033-B2 Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient INSTITUT PASTEUR KOREA (KR) 2021-10-19 US disclosed
US-20200031816-A1 NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT ST PHARM CO., LTD. (KR) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031816-A1 NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT ZC3HAV1, ZC3HAV1L, HAVCR2 PTK2 4377/4885GSK3B 658/4885NPC1 295/4885
US-11149033-B2 Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient ZC3HAV1, ZC3HAV1L, HAVCR2 PTK2 4380/4885GSK3B 589/4885NPC1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.